Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Pharmala Biotech Holdings Inc C.MDMA

Alternate Symbol(s):  MDXXF

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.


CSE:MDMA - Post by User

Comment by inviolablspiriton Oct 08, 2024 1:28pm
89 Views
Post# 36258115

RE:PharmAla to supply the University of Texas, San Antonio

RE:PharmAla to supply the University of Texas, San AntonioI believe these news releases to supply research clinics in the US will continue biweekly to weekly.  I would certainly love to see an additional news release in the same week to continue the upward pressure and put some of these penny flippers behind us.  

As I mentioned in a past post the unfortunate decision made by the FDA would open the doors for Pharmala in the US for supplying clinical trials.   Pharmala's focus has always been supplying outside the US (i.e. Austrialia, Europe and S. America), so when the FDA handed down their decision this became a bonus upside for Phamala.  So far...  Hopkins, Harvard, San Antonio...  and I'm sure more to come.  

Pharmala's team is currently in Europe (Oct. 7-11) for the CPHI conference in Milan meeting with a number of potential distribution partners.   So we may hear of some possible news from these meetings in the near future.  

With these continued news releases the stock should begin a nice steady climb.  Depending on how long to the next news release the stock should fine support around the 9-10 cent mark.   Until that next news release this may be the last time to pick up shares under 10 cents, as I'm sure TD and CIBC will hammer it back down a bit.  Hopefully these shares can find their way into more and more hands of longer term investors, so there will be less and less shares available on the asks and in the hands of the penny flippers.  

 
<< Previous
Bullboard Posts
Next >>